TY  - GEN
N2  - This Executive Summary concisely presents the results of an independent study commissioned by the World Intellectual Property Organization (WIPO)’s Global Challenges Division looking at the role played by intellectual property (IP) and technology transfer in the development, production and distribution of vaccines used to address the COVID-19 pandemic. The study uses a case-study approach to provide an in-depth analysis of some of the different approaches adopted by ten different global vaccine manufacturers, with respect to their funding, procurement, vaccine development and IP strategies (including licensing, technology transfer and access provisions). These experiences and lessons learnt provide practical insights to guide global policy-making on IP, health and access issues.
DO  - 10.34667/tind.48614
DO  - doi
AB  - This Executive Summary concisely presents the results of an independent study commissioned by the World Intellectual Property Organization (WIPO)’s Global Challenges Division looking at the role played by intellectual property (IP) and technology transfer in the development, production and distribution of vaccines used to address the COVID-19 pandemic. The study uses a case-study approach to provide an in-depth analysis of some of the different approaches adopted by ten different global vaccine manufacturers, with respect to their funding, procurement, vaccine development and IP strategies (including licensing, technology transfer and access provisions). These experiences and lessons learnt provide practical insights to guide global policy-making on IP, health and access issues.
T1  - Intellectual Property and Technology Transfer for COVID-19 Vaccines :Assessment of the record - Executive Summary.
AU  - Abbott, Frederick M.,
L1  - https://tind.wipo.int/record/48614/files/wipo-pub-rn2023-39-exec-en-intellectual-property-and-technology-transfer-for-covid-19-vaccines-assessment-of-the-record.pdf
VL  - No. RN2023-39
LA  - eng
ID  - 48614
L4  - https://tind.wipo.int/record/48614/files/wipo-pub-rn2023-39-exec-en-intellectual-property-and-technology-transfer-for-covid-19-vaccines-assessment-of-the-record.pdf
KW  - Patents
KW  - Intellectual property
KW  - Science and technology
KW  - Technology transfer
KW  - Intellectual property.
KW  - Patents.
KW  - Technology transfer
TI  - Intellectual Property and Technology Transfer for COVID-19 Vaccines :Assessment of the record - Executive Summary.
L2  - https://tind.wipo.int/record/48614/files/wipo-pub-rn2023-39-exec-en-intellectual-property-and-technology-transfer-for-covid-19-vaccines-assessment-of-the-record.pdf
LK  - https://tind.wipo.int/record/48614/files/wipo-pub-rn2023-39-exec-en-intellectual-property-and-technology-transfer-for-covid-19-vaccines-assessment-of-the-record.pdf
UR  - https://tind.wipo.int/record/48614/files/wipo-pub-rn2023-39-exec-en-intellectual-property-and-technology-transfer-for-covid-19-vaccines-assessment-of-the-record.pdf
ER  -